Overview of Current Treatment Landscape of ALK Inhibitors

Future work may need to assess whether extended hospital stays improve surgical care outcomes during disasters, according to one of the study authors.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Phase 2 data support further investigation of trastuzumab rezetecan as a treatment for patients with HER2-mutant non–small cell lung cancer.

Ivonescimab demonstrated a broad prolongation of PFS across various prespecified subgroups in patients with treatment-naïve, PD-L1–positive NSCLC.